Sen. Bill Cassidy plots a path for more commercially viable cell and gene therapies

Zachary Brennan

Senior Editor

With the likely approval of a new gene editing therapy coming this week for CRISPR Therapeutics and Vertex, Sen. Bill Cassidy (R-LA) on Tuesday called …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sen. Bill Cassidy plots a path for more commercially viable cell and gene therapies

Zachary Brennan

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

At Jefferies, all that manufacturers want to talk about is GLP-1s

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Sen. Bill Cas­sidy plots a path for more com­mer­cial­ly vi­able cell and gene ther­a­pies

Zachary Brennan

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Sen. Bill Cassidy plots a path for more commercially viable cell and gene therapies

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

At Jefferies, all that manufacturers want to talk about is GLP-1s

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?